FULL POSTER SESSION ABSTRACTSmetabolite production, hyphal morphology, conidiation, and pellet formation [1]. Here we describe the characterization of PcVelB, PcVelC, and PcVosA asnovel subunits of this velvet complex. Using yeast two-hybrid analysis and bimolecular fluorescence complementation (BiFC), we demonstrate that allvelvet proteins are part of an interaction network. Functional analyses using single and double knockout strains generated by the FLP/FRT recombinationsystem [2] clearly indicate that velvet subunits have opposing roles in the regulation of penicillin biosynthesis and light-dependent conidiation. Moststrikingly, a direct interaction of PcVelB with an enzyme of the penicillin biosynthesis pathway, the isopenicillin N synthase was identified during yeast twohybridanalysis with PcVelB as bait. This surprising interaction was confirmed with BiFC in vivo, thereby localizing the interaction in dot-like structures inthe cytoplasm. Our discovery of a direct interaction of the isopenicillin N synthase with a subunit of the velvet complex implies a novel regulatorymechanism how enzymes of penicillin biosynthesis are regulated at the molecular level. The results provided here contribute to our fundamentalunderstanding of the function of velvet subunits as part of a regulatory network mediating signals responsible for morphology and secondary metabolism,and will be instrumental in generating mutants with newly derived properties that are relevant to strain improvement programs.[1] Hoff B, Kamerewerd J, Sigl C, Mitterbauer R, Zadra I, Kürnsteiner H, Kück U (2010) Eukaryot Cell: 9:1236-50[2] Kopke K, Hoff B, Kück U (2010) Appl Environ Microbiol 76:4664-4674.50. Genome mining reveals the evolutionary origin and biosynthetic potential of basidiomycete polyketide synthases. Gerald Lackner, Mathias Misiek,Jana Braesel, Dirk Hoffmeister. Pharmaceutical Biology, Friedrich-Schiller-University Jena, Germany.Polyketide biosynthesis is a rich source of pharmaceutically active secondary metabolites present in fungi. Besides lipid-lowering drug lovastatin, manyinfamous toxins are produced via this pathway. While abundant in Aspergillus, only few polyketides have been isolated from basidiomycetes. Highthroughput genome sequencing projects, however, now help estimate the genetic capacity of basidiomycetes to biosynthesize polyketide derivatives. Byinspection of 35 sequenced basidiomycete genomes we identified and annotated 111 iterative type I and three type III polyketide synthase (PKS) genes.Phylogenetic analyses of KS genes imply that all main families of fungal PKS had already evolved before the Ascomycota and Basidiomycota diverged. Acomparison of genomic data and metabolomic records shows that the number of polyketide genes surpasses the number of known polyketidesconsiderably. This work might serve as a guide for upcoming genomic mining projects to discover novel polyketide derivates from mushrooms.51. Engineering Cyclic Peptide Biosynthesis in Poisonous Mushrooms. Hong Luo, John S. Scott Craig, Robert M. Sgambelluri, Sung-Yong Hong, Jonathan D.Walton. Department of Energy Plant Research Laboratory, Michigan State University, E. Lansing, MI 48824, United States.Ninety percent of fatal mushroom poisonings are caused by alpha-amanitin and related bicyclic peptides found in some species of Amanita, Galerina,Lepiota, and Conocybe. We showed that the amatoxins (mainly amanitins) and related phallotoxins are synthesized on ribosomes in A. bisporigera and theunrelated mushroom G. marginata. The primary gene products are short (34-35 amino acid) proproteins that are initially processed by a dedicated prolyloligopeptidase. A genome survey sequence of A. bisporigera suggested that it has a repertoire of over 40 cyclic peptides, all produced on a singlebiosynthetic scaffold. Members of this extended gene family are characterized by conserved upstream and downstream amino acid sequences, includingtwo invariant proline residues, flanking a six to ten-amino acid “hypervariable” region that encodes the amino acids found in the mature toxins (orpredicted toxins). The evidence indicates that A. bisporigera has evolved a combinatorial strategy that could in principle biosynthesize billions of smallcyclic peptides. In order to study the other steps in amanitin biosynthesis, and to engineer novel cyclic peptides, we have developed a transformationstrategy for the amanitin-producing mushroom G. marginata. This first transformation method uses Agrobacterium-mediated transformation followed byhygromycin selection. Taking advantage of this platform, we are introducing artificial toxin genes that are deliberately designed to provide insights into thepathway. The synthetic genes include those that encode the cyclic octapeptide beta-amanitin, the heptapeptides phalloidin and phallacidin, examples ofthe toxin gene family known from A. bisporigera but not G. marginata, and randomly generated artificial sequences. Currently, thousands of transformantshave been generated through an efficient pipeline and the transformants are being analyzed for production of the expected products. If successful, thenovel peptides will be screened in a number of assays including RNA polymerase (the site of action of alpha-amanitin), membrane ion channels,pathogenic bacteria, and cancer cell lines.52. Spatial assessment of oxidative and enzymatic reactions in brown rotted wood. Jon R. Menke 1 , Jae San Ryu 2,5,6 , Gerald N. Presley 1 , Shona M. Duncan 1 ,Joel A. Jurgens 3 , Robert A. Blanchette 3 , Timothy R. Filley 4 , Kenneth E. Hammel 2,5 , Jonathan S. Schilling 1 . 1) Department of Bioproducts and BiosystemsEngineering, University of Minnesota, St. Paul, MN; 2) Department of Bacteriology, University of Wisconsin, Madison, WI; 3) Department of PlantPathology, University of Minnesota, St. Paul, MN; 4) Department of Earth and Atmospheric Sciences and the Purdue Climate Change Research Center,Purdue University, West Lafayette, IN; 5) Institute for Microbial and Biochemical Technology, U.S. Forest Products Laboratory, Madison, WI; 6) Eco-Friendliness Research Department, Gyeongsangnam-do Agricultural Research and Extension Services, Republic of Korea.Brown rot fungi are theorized to use coordinated free radical oxidations and enzymatic reactions to consume wood. Though likely incompatible in vitro, itis proposed these reactions occur concurrently during brown rot of wood. We mapped and then compared fungal growth, wood modifications related tonon-enzymatic mechanisms, and cellulase activity in thin spruce ‘wafers’ to investigate the degree of spatial coincidence of these reactions in wooddegraded by Postia placenta. Nearly coincident oxidative and enzymatic reaction fronts were observed behind the most advanced hyphal tips, suggesting afine-scale (likely sub-micron) spatial or biochemical extracellular mechanism may protect both hyphae and enzymes from oxidative stress. To furtherinvestigate a possible role of enzymatic reactions in the primary depolymerization of lignocellulose during brown rot, we have initiated a study totemporally assess the depth of penetration of an endoglucanase into wood cells during this process. Previous studies have used the marker proteinsinsulin (5.7 kDa), myoglobin (17.6 kDa), and ovalbumin (44.4 kDa); and immunocytochemical electron microscopy to demonstrate the ability of the twosmaller proteins to infiltrate the cell walls of rotted wood. The Postia placenta endoglucanase Cel5B (PpCel5B) has a theoretical molecular weight of 34.6kDa, which is considerably lower than the molecular weight of ovalbumin. Our approach involves using a polyclonal antibody raised against PpCel5Bheterologously expressed in Pichia pastorius. This antibody will be used to assess the extent to which a native brown rot endoglucanase is able topenetrate Pinus resinosa cells. Given the common supposition that pore size prevents brown rot fungal endoglucanases from accessing wood secondarywalls, even in late decay stages, this work will provide a direct assessment of enzyme ingress.53. Molecular biological basis for statin resistance in naturally statin-producing organisms. Ana Rems, Rasmus Frandsen. DTU Systems Biology, TechnicalUniversity of Denmark, Kongens Lyngby, Denmark.Secondary metabolites can be toxic to the organism producing them; therefore gene clusters for biosynthesis of secondary metabolites often includegenes responsible for the organism’s self-resistance to the toxic compounds. One such gene cluster is the compactin (ML-236B) cluster in Penicilliumsolitum. Compactin is an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, and is used as a precursor for production of the cholesterolloweringdrug pravastatin. The compactin gene cluster includes two genes encoding proteins that may confer the self-resistance to compactin and its134
FULL POSTER SESSION ABSTRACTSsecretion [1]. The mlcD gene encodes a putative 'HMG-CoA reductase-like protein’, and mlcE encodes a putative efflux pump. However, the function ofthese two putative proteins has not yet been confirmed. We aim to elucidate the biological basis for compactin resistance in the compactin-producingorganism. A codon-optimized version of the mlcD gene was inserted into the Saccharomyces cerevisiae genome. The constructed yeast strain was testedfor sensitivity to lovastatin, a statin structurally similar to compactin, by growing the strain on media containing lovastatin. The strain showed an increasedresistance to lovastatin compared to the wild-type strain. Furthermore, we investigated if MlcD confers the resistance by functional complementation ofthe endogenous HMG-CoA reductases in S. cerevisiae. There are two isozymes of HMG-CoA reductase in yeast, HMG1 and HMG2, both involved in thesterol biosynthetic pathway, which leads to the synthesis of ergosterol. Following deletion of HMG1 and HMG2 genes in S. cerevisiae, we inserted the mlcDgene into the knockout mutants, and tested the resulted strains for sensitivity to lovastatin. The HMG1 and HMG2 knockout mutants were unable to growon minimal media and had an increased sensitivity to lovastatin on rich media. However, insertion of the mlcD gene restored the growth of the yeastmutants and increased their resistance to lovastatin. These results show that MlcD complements the activity of the deleted HMG-CoA reductases, enablingsynthesis of ergosterol in yeast. In addition MlcD confers statin resistance by being insensitive to the inhibiting effects of statins. Reference: [1] Abe Y.,Suzuki T., Ono C., Iwamoto K., Hosobuchi M., Yoshikawa H. Mol Genet Genomics 2002, 267, 5:636-46.54. Molecular genetic characterization of secondary metabolism pathways in Asperillus species. Clay Wang 1 , Yiming Chiang 1 , Nancy Keller 3 , KennethBruno 4 , Scott Baker 4 , Chun jun Guo 1 , James Sanchez 1 , Benjamin Knox 4 , Alexandra Soukup 3 , Jin Woo Bok 3 , Manmeet Ahuja 2 , Ruth Entwistle 2 , Liz Oakley 2 ,Shu-lin Chang 1 , Hsu-Hua Yeh 1 , Mike Praseuth 1 , Berl Oakley 2 . 1) Pharma Sci & Chemistry, Univ Southern California, Los Angeles, CA; 2) Department ofMolecular Biosciences, University of Kansas; 3) Department of Medical Microbiology and Immunology and Department of Bacteriology, University ofWisconsin Madison; 4) Pacific Northwest National Laboratory.Advances in next generation DNA sequencing have provided a large number of fungal genome sequences in public databases. Within these genomes arelarge numbers of cryptic secondary metabolism pathways. Data will be presented where we use a comparative genomics approaches to identify theproducts of these cryptic pathways. Next we use a gene knock out approach to create mutants followed by isolation and characterization of intermediatesand shunt products. Using this approach we have been able to identify the products of a meroterpenoid pathway in A. terreus.55. A branched biosynthetic pathway is involved in production of roquefortine and related compounds in Penicillium chrysogenum. Hazrat Ali 1,2 , MarcoRies 3 , Jeroen Nijland 1,2 , Peter Lankhorst 4 , Thomas Hankemeier 3,5 , Roel Bovenberg 4,6 , Rob Vreeken 3,5 , Arnold Driessen 1,2* . 1) Molecular Microbiology,Groningen Biomolecular Sciences and Biotechnology Institute, Zernike Institute for Advanced Materials, University of Groningen, The Netherlands; 2)Kluyver Centre for Genomics of Industrial Fermentations, Julianalaan 67, 2628BC Delft, The Netherlands; 3) 3Division of Analytical Biosciences,Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands; 4) DSM Biotechnology Center, Alexander Fleminglaan 1, 2613 AX Delft,The Netherlands; 5) Netherlands Metabolomics Centre, Leiden University, Leiden, The Netherlands; 6) Synthetic Biology and Cell Engineering, GroningenBiomolecular Sciences and Biotechnology Institute, University of Groningen, The Netherlands.Profiling and structural elucidation of secondary metabolites produced by the filamentous fungus Penicillium chrysogenum and derived deletion strainswere used to identify the various metabolites and enzymatic steps belonging to the roquefortine/meleagrin pathway. Major abundant metabolites of thispathway were identified as histidyltryptophanyldiketopiperazine (HTD), dehydrohistidyltryptophanyldiketopiperazine (DHTD), roquefortine D,roquefortine C, glandicoline A, glandicoline B and meleagrin. Specific genes could be assigned to each enzymatic reaction step. The nonribosomal peptidesynthetase RoqA accepts histidine and tryptophan as substrates leading to the production of the diketopiperazine HTD. DHTD, previously suggested to bea degradation product of roquefortine C, was found to be derived from HTD involving the cytochrome P450 oxidoreductase RoqR. Thedimethylallyltryptophan synthetase RoqD prenylates both HTD and DHTD yielding the products roquefortine D and roquefortine C, respectively. This leadsto a branch in the otherwise linear pathway. Roquefortine C is subsequently converted into meleagrin with glandicoline A and B as intermediates, involvingtwo monooxygenases (RoqM and RoqO) and a methyltransferase (RoqN). It is concluded that roquefortine C and meleagrin are derived from a branchedbiosynthetic pathway rather than a linear pathway as suggested in literature.56. A biosynthetic gene cluster for the antifungal metabolite phomenoic acid in the plant pathogenic fungus, Leptosphaeria maculans. Candace Elliott 1 ,Damien Callahan 2 , Daniel Schwenk 3 , Markus Nett 4 , Dirk Hoffmeister 3 , Barbara Howlett 1 . 1) School of Botany, University of Melbourne, Melbourne,Australia; 2) Metabolomics Australia, School of Botany, The University of Melbourne, Victoria 3010, Australia; 3) Friedrich-Schiller-Universität, DepartmentPharmaceutical Biology at the Hans-Knöll-Institute, Beutenbergstrasse 11a, 07745 Jena, Germany; 4) Leibniz Institute for Natural Product Research andInfection Biology e.V., Hans-Knöll-Institute, Beutenbergstrasse 11a, 07745 Jena, Germany.Phomenoic acid, a long chain aliphatic carboxylic acid, is a major metabolite produced by Leptosphaeria maculans, a fungal pathogen of Brassica napus(canola). Early biosynthetic studies suggested that the methyl group derived from S-adenosylmethionine (SAM), whereas the incorporation pattern of[13C] acetate suggested a polyketidic origin of the linear portion of phomenoic acid (Devys et al., 1984). We have used domain modelling to predict acandidate polyketide synthase (PKS) for phomenoic acid biosynthesis. Of the 15 predicted polyketide synthases (PKS) in the L. maculans genome, sevenwere reducing with the appropriate domains (KS - keto-synthase; AT - acyltransferase; DH - dehydratase; MT- methyltransferase; ER - enoylreductase; KR -ketoreductase; ACP- acyl carrier protein) for the biosynthesis of phomenoic acid. The most highly expressed of these seven genes, PKS2, was silenced to10% of that of wild type levels and the resultant mutant produced 25 times less phomenoic acid than the wild type did, indicating that PKS2 is involved inphomenoic acid biosynthesis. This gene is part of a cluster and nearby genes are co-regulated. A two-fold reduction in the expression of the adjacenttranscriptional regulator C6TF, led to at least a 20-fold reduction in expression of PKS2, as well as of other genes in the cluster (P450, YogA, RTA1 andMFS), but not of the adjacent ChoK or a hypothetical gene (Hyp). This down-regulated mutant also showed a marked reduction in phomenoic acidproduction. Phomenoic acid is toxic towards another canola pathogen Leptosphaeria biglobosa ‘canadensis’, but L. maculans and to a lesser extent thewheat pathogen, Stagonospora nodorum are more tolerant. Phomenoic acid may play a role in allowing L. maculans to outcompete other fungi in itsenvironmental niche.57. Exploring and Manipulating Pleuromutilin Production. Patrick M Hayes 1 , Russell J Cox 2 , Andy M Bailey 1 , Gary D Foster 1 . 1) School of BiologicalSciences, University of Bristol, Woodland Road, Bristol BS8 1UG, UK; 2) School of Chemistry, University of Bristol, Bristol BS8 1TS, UK.Antibiotic resistance has arisen in a significant number of human pathogens, antibiotic discovery and development is, however, currently not keepingpace. This has lead to the reinvestigation of some naturally produced antibiotic compounds which act in a manner that avoids common resistancemechanisms. Pleuromutilin is one such compound with activity against bacteria such as Methicillin Resistant Staphylococcus aureus (MRSA). Pleuromutilinis generally synthesised at a low titre by its native producer Clitopilus passeckerianus and as such research into its biosynthesis may enable yield increases.This project has taken a multifaceted approach to manipulate the Pleuromutilin biosynthetic gene cluster in a variety of fungal organisms. Within C.<strong>27th</strong> <strong>Fungal</strong> <strong>Genetics</strong> <strong>Conference</strong> | 135
- Page 1:
Asilomar Conference GroundsMarch 12
- Page 7 and 8:
SCHEDULE OF EVENTSFriday, March 157
- Page 10 and 11:
EXHIBITSThe following companies hav
- Page 12 and 13:
CONCURRENT SESSIONS SCHEDULESWednes
- Page 14:
CONCURRENT SESSIONS SCHEDULESWednes
- Page 17 and 18:
CONCURRENT SESSIONS SCHEDULESThursd
- Page 19:
CONCURRENT SESSIONS SCHEDULESFriday
- Page 22 and 23:
CONCURRENT SESSIONS SCHEDULESSaturd
- Page 24:
CONCURRENT SESSIONS SCHEDULESSaturd
- Page 27 and 28:
PLENARY SESSION ABSTRACTSThursday,
- Page 29 and 30:
PLENARY SESSION ABSTRACTSFriday, Ma
- Page 31 and 32:
PLENARY SESSION ABSTRACTSSaturday,
- Page 33 and 34:
CONCURRENT SESSION ABSTRACTSWednesd
- Page 35 and 36:
CONCURRENT SESSION ABSTRACTSUnravel
- Page 37 and 38:
CONCURRENT SESSION ABSTRACTSSynergi
- Page 39 and 40:
CONCURRENT SESSION ABSTRACTSWednesd
- Page 41 and 42:
CONCURRENT SESSION ABSTRACTSWednesd
- Page 43 and 44:
CONCURRENT SESSION ABSTRACTSWednesd
- Page 45 and 46:
CONCURRENT SESSION ABSTRACTSA draft
- Page 47 and 48:
CONCURRENT SESSION ABSTRACTSRegulat
- Page 49 and 50:
CONCURRENT SESSION ABSTRACTSWednesd
- Page 51 and 52:
CONCURRENT SESSION ABSTRACTSThursda
- Page 53 and 54:
CONCURRENT SESSION ABSTRACTSThursda
- Page 55 and 56:
CONCURRENT SESSION ABSTRACTSThursda
- Page 57 and 58:
CONCURRENT SESSION ABSTRACTSThursda
- Page 59 and 60:
CONCURRENT SESSION ABSTRACTSThursda
- Page 61 and 62:
CONCURRENT SESSION ABSTRACTSThe mut
- Page 63 and 64:
CONCURRENT SESSION ABSTRACTSInnate
- Page 65 and 66:
CONCURRENT SESSION ABSTRACTSThursda
- Page 67 and 68:
CONCURRENT SESSION ABSTRACTSGenome-
- Page 69 and 70:
CONCURRENT SESSION ABSTRACTSIdentif
- Page 71 and 72:
CONCURRENT SESSION ABSTRACTSFriday,
- Page 73 and 74:
CONCURRENT SESSION ABSTRACTSFriday,
- Page 75 and 76:
CONCURRENT SESSION ABSTRACTSThe Scl
- Page 77 and 78:
CONCURRENT SESSION ABSTRACTSThe rol
- Page 79 and 80:
CONCURRENT SESSION ABSTRACTSFriday,
- Page 81 and 82:
CONCURRENT SESSION ABSTRACTSCompari
- Page 83 and 84:
CONCURRENT SESSION ABSTRACTSNovel t
- Page 85 and 86:
CONCURRENT SESSION ABSTRACTSFriday,
- Page 87 and 88: CONCURRENT SESSION ABSTRACTSEffect
- Page 89 and 90: CONCURRENT SESSION ABSTRACTSCommon
- Page 91 and 92: CONCURRENT SESSION ABSTRACTSSaturda
- Page 93 and 94: CONCURRENT SESSION ABSTRACTSSeconda
- Page 95 and 96: CONCURRENT SESSION ABSTRACTSSheddin
- Page 97 and 98: CONCURRENT SESSION ABSTRACTSSaturda
- Page 99 and 100: CONCURRENT SESSION ABSTRACTSSaturda
- Page 101 and 102: CONCURRENT SESSION ABSTRACTSSaturda
- Page 103 and 104: CONCURRENT SESSION ABSTRACTSprocess
- Page 105 and 106: CONCURRENT SESSION ABSTRACTSSpecifi
- Page 107 and 108: LISTING OF ALL POSTER ABSTRACTSBioc
- Page 109 and 110: LISTING OF ALL POSTER ABSTRACTS81.
- Page 111 and 112: LISTING OF ALL POSTER ABSTRACTS160.
- Page 113 and 114: LISTING OF ALL POSTER ABSTRACTS239.
- Page 115 and 116: LISTING OF ALL POSTER ABSTRACTS322.
- Page 117 and 118: LISTING OF ALL POSTER ABSTRACTS401.
- Page 119 and 120: LISTING OF ALL POSTER ABSTRACTSmedi
- Page 121 and 122: LISTING OF ALL POSTER ABSTRACTS558.
- Page 123 and 124: LISTING OF ALL POSTER ABSTRACTS640.
- Page 125 and 126: LISTING OF ALL POSTER ABSTRACTS723.
- Page 127 and 128: FULL POSTER SESSION ABSTRACTS5. Cha
- Page 129 and 130: FULL POSTER SESSION ABSTRACTS13. In
- Page 131 and 132: FULL POSTER SESSION ABSTRACTSbioche
- Page 133 and 134: FULL POSTER SESSION ABSTRACTS30. Me
- Page 135 and 136: FULL POSTER SESSION ABSTRACTS38. Me
- Page 137: FULL POSTER SESSION ABSTRACTSidenti
- Page 141 and 142: FULL POSTER SESSION ABSTRACTSinvolv
- Page 143 and 144: FULL POSTER SESSION ABSTRACTSdiploi
- Page 145 and 146: FULL POSTER SESSION ABSTRACTSSaccha
- Page 147 and 148: FULL POSTER SESSION ABSTRACTSresist
- Page 149 and 150: FULL POSTER SESSION ABSTRACTS96. Ce
- Page 151 and 152: FULL POSTER SESSION ABSTRACTS104. M
- Page 153 and 154: FULL POSTER SESSION ABSTRACTScan ex
- Page 155 and 156: FULL POSTER SESSION ABSTRACTSturgor
- Page 157 and 158: FULL POSTER SESSION ABSTRACTSlike p
- Page 159 and 160: FULL POSTER SESSION ABSTRACTSIndoor
- Page 161 and 162: FULL POSTER SESSION ABSTRACTSlength
- Page 163 and 164: FULL POSTER SESSION ABSTRACTSA scre
- Page 165 and 166: FULL POSTER SESSION ABSTRACTSthen q
- Page 167 and 168: FULL POSTER SESSION ABSTRACTS170. S
- Page 169 and 170: FULL POSTER SESSION ABSTRACTSof sup
- Page 171 and 172: FULL POSTER SESSION ABSTRACTSis fzo
- Page 173 and 174: FULL POSTER SESSION ABSTRACTSgrowth
- Page 175 and 176: FULL POSTER SESSION ABSTRACTSSeq da
- Page 177 and 178: FULL POSTER SESSION ABSTRACTS212. T
- Page 179 and 180: FULL POSTER SESSION ABSTRACTSCompar
- Page 181 and 182: FULL POSTER SESSION ABSTRACTSmore g
- Page 183 and 184: FULL POSTER SESSION ABSTRACTSmolecu
- Page 185 and 186: FULL POSTER SESSION ABSTRACTSunexpe
- Page 187 and 188: FULL POSTER SESSION ABSTRACTSrapid
- Page 189 and 190:
FULL POSTER SESSION ABSTRACTS260. T
- Page 191 and 192:
FULL POSTER SESSION ABSTRACTSFusari
- Page 193 and 194:
FULL POSTER SESSION ABSTRACTSScienc
- Page 195 and 196:
FULL POSTER SESSION ABSTRACTS286. G
- Page 197 and 198:
FULL POSTER SESSION ABSTRACTSincomp
- Page 199 and 200:
FULL POSTER SESSION ABSTRACTSfound
- Page 201 and 202:
FULL POSTER SESSION ABSTRACTS312. I
- Page 203 and 204:
FULL POSTER SESSION ABSTRACTSall th
- Page 205 and 206:
FULL POSTER SESSION ABSTRACTSPia La
- Page 207 and 208:
FULL POSTER SESSION ABSTRACTS335. A
- Page 209 and 210:
FULL POSTER SESSION ABSTRACTS342. F
- Page 211 and 212:
FULL POSTER SESSION ABSTRACTSThis i
- Page 213 and 214:
FULL POSTER SESSION ABSTRACTSJacobs
- Page 215 and 216:
FULL POSTER SESSION ABSTRACTScalciu
- Page 217 and 218:
FULL POSTER SESSION ABSTRACTSThe ab
- Page 219 and 220:
FULL POSTER SESSION ABSTRACTSexpres
- Page 221 and 222:
FULL POSTER SESSION ABSTRACTS394. F
- Page 223 and 224:
FULL POSTER SESSION ABSTRACTS398. U
- Page 225 and 226:
FULL POSTER SESSION ABSTRACTSthe id
- Page 227 and 228:
FULL POSTER SESSION ABSTRACTS415. A
- Page 229 and 230:
FULL POSTER SESSION ABSTRACTSAcuM b
- Page 231 and 232:
FULL POSTER SESSION ABSTRACTSdiverg
- Page 233 and 234:
FULL POSTER SESSION ABSTRACTSBck1 f
- Page 235 and 236:
FULL POSTER SESSION ABSTRACTSin the
- Page 237 and 238:
FULL POSTER SESSION ABSTRACTS455. T
- Page 239 and 240:
FULL POSTER SESSION ABSTRACTSor hos
- Page 241 and 242:
FULL POSTER SESSION ABSTRACTSfragme
- Page 243 and 244:
FULL POSTER SESSION ABSTRACTSenhanc
- Page 245 and 246:
FULL POSTER SESSION ABSTRACTSassess
- Page 247 and 248:
FULL POSTER SESSION ABSTRACTSmating
- Page 249 and 250:
FULL POSTER SESSION ABSTRACTScommon
- Page 251 and 252:
FULL POSTER SESSION ABSTRACTSOne of
- Page 253 and 254:
FULL POSTER SESSION ABSTRACTScells
- Page 255 and 256:
FULL POSTER SESSION ABSTRACTSof Ave
- Page 257 and 258:
FULL POSTER SESSION ABSTRACTSascaro
- Page 259 and 260:
FULL POSTER SESSION ABSTRACTSis a n
- Page 261 and 262:
FULL POSTER SESSION ABSTRACTSand th
- Page 263 and 264:
FULL POSTER SESSION ABSTRACTSCiuffe
- Page 265 and 266:
FULL POSTER SESSION ABSTRACTSon oth
- Page 267 and 268:
FULL POSTER SESSION ABSTRACTScopies
- Page 269 and 270:
FULL POSTER SESSION ABSTRACTSChem.
- Page 271 and 272:
FULL POSTER SESSION ABSTRACTS593. C
- Page 273 and 274:
FULL POSTER SESSION ABSTRACTS601. P
- Page 275 and 276:
FULL POSTER SESSION ABSTRACTSE.elym
- Page 277 and 278:
FULL POSTER SESSION ABSTRACTSThe de
- Page 279 and 280:
FULL POSTER SESSION ABSTRACTSMicrob
- Page 281 and 282:
FULL POSTER SESSION ABSTRACTSchromo
- Page 283 and 284:
FULL POSTER SESSION ABSTRACTSmating
- Page 285 and 286:
FULL POSTER SESSION ABSTRACTSAt the
- Page 287 and 288:
FULL POSTER SESSION ABSTRACTSemerge
- Page 289 and 290:
FULL POSTER SESSION ABSTRACTS666. G
- Page 291 and 292:
FULL POSTER SESSION ABSTRACTSof che
- Page 293 and 294:
FULL POSTER SESSION ABSTRACTSthe lo
- Page 295 and 296:
FULL POSTER SESSION ABSTRACTSin the
- Page 297 and 298:
FULL POSTER SESSION ABSTRACTSpotent
- Page 299 and 300:
FULL POSTER SESSION ABSTRACTSpoint
- Page 301 and 302:
FULL POSTER SESSION ABSTRACTS716. p
- Page 303 and 304:
FULL POSTER SESSION ABSTRACTSnatura
- Page 305 and 306:
FULL POSTER SESSION ABSTRACTSelemen
- Page 307 and 308:
KEYWORD LISTABC proteins ..........
- Page 309 and 310:
KEYWORD LISThigh temperature growth
- Page 311 and 312:
AUTHOR LISTBolton, Melvin D. ......
- Page 313 and 314:
AUTHOR LISTFrancis, Martin ........
- Page 315 and 316:
AUTHOR LISTKawamoto, Susumu... 427,
- Page 317 and 318:
AUTHOR LISTNNadimi, Maryam ........
- Page 319 and 320:
AUTHOR LISTSenftleben, Dominik ....
- Page 321 and 322:
AUTHOR LISTYablonowski, Jacob .....
- Page 323 and 324:
LIST OF PARTICIPANTSLeslie G Beresf
- Page 325 and 326:
LIST OF PARTICIPANTSTim A DahlmannR
- Page 327 and 328:
LIST OF PARTICIPANTSIgor V Grigorie
- Page 329 and 330:
LIST OF PARTICIPANTSMasayuki KameiT
- Page 331 and 332:
LIST OF PARTICIPANTSGeorgiana MayUn
- Page 333 and 334:
LIST OF PARTICIPANTSNadia PontsINRA
- Page 335 and 336:
LIST OF PARTICIPANTSFrancis SmetUni
- Page 337 and 338:
LIST OF PARTICIPANTSAric E WiestUni